Literature DB >> 622086

Correction of human cyclic neutropenia with prednisolone.

D G Wright, A S Fauci, D C Dale, S M Wolff.   

Abstract

A 70-year-old woman with cyclic neutropenia was treated with 16 mg of etiocholanolone and 25 mg of prednisolone intramuscularly every other day. During 14 weeks' treatment amplitude of cyclic fluctuations in neutrophil counts gradually decreased, but pretreatment cycles returned promptly after treatment was stopped. Prednisolone alone every other day (25 mg) reproduced this result, and by 23 weeks, neutrophil counts became stable at about 1500 per cubic millimeter. tcycling of monocytes, platelets and reticulocytes was also eliminated, as were symptoms that had accompanied neutropenic periods. In addition, bone-marrow neutrophil precursors and neutrophil marrow reserves were stabilized. The patient was subsequently maintained satisfactorily with oral prednisolone, 20 mg every other day. These studies demonstrate that the discontinuous myeloid maturation that occurs in cyclic neutropenia can be corrected with prednisolone every other day.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 622086     DOI: 10.1056/NEJM197802092980602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  5 in total

1.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

2.  The effect of recombinant granulocyte colony-stimulating factor on oral and periodontal manifestations in a patient with cyclic neutropenia: a case report.

Authors:  Sergio Matarasso; Vincenzo Daniele; Vincenzo Iorio Siciliano; Michele D Mignogna; Gianmaria Andreuccetti; Carlo Cafiero
Journal:  Int J Dent       Date:  2010-02-18

3.  Steroid responsive cyclical neutropenia.

Authors:  G A Young; H J Iland; S F Deveridge; P R Forrest; P C Vincent
Journal:  Blut       Date:  1984-03

4.  Abnormal responses of myeloid progenitor cells to granulocyte-macrophage colony-stimulating factor in human cyclic neutropenia.

Authors:  D G Wright; V F LaRussa; A J Salvado; R D Knight
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor.

Authors:  Roger M Lyons; Sharon T Wilks; Shelby Young; Gail L Brown
Journal:  J Hematol Oncol       Date:  2011-11-02       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.